Publication Date:
2016-09-08
Description:
Key Points Venetoclax demonstrates potent in vitro and in vivo single-agent activity in MLL-rearranged ALL xenografts. Clinically efficacious BH3-mimetic therapy for other high-risk ALL subtypes is likely to require concurrent BCL-2 and BCL-XL inhibition.
Print ISSN:
0006-4971
Electronic ISSN:
1528-0020
Topics:
Biology
,
Medicine
Permalink